Press Releases

Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for an update of the Wegovy® (semaglutide 2.4 mg) label in the European Union (EU). The label update incorporates data showing that Wegovy®, when added to standard of care, can reduce heart failure-related symptoms and improve physical limitations and exercise function in people with obesity-related HFpEF, with or without ty

Galmed Pharmaceuticals Ltd. a clinical-stage biopharmaceutical company for fibroinflammatory indications announced today that based on the recently published results from the Open-Label part of its Phase 3 NASH study, new scientific publications on the role of SCD1 as a critical metabolic signaling hub as well as an extended cash runway, it plans to broaden its drug development activities.  The planned expansion consists of two additional programs over the next two years. One p

Eleva, a pioneer in unlocking difficult-to-produce biologics based on a breakthrough manufacturing platform, announced today the appointment of Dr. Elisabeth Lackner to its Supervisory Board. Dr. Lackner’s appointment adds broad biopharmaceutical industry expertise to Eleva’s board including insights into clinical development, contract research and manufacturing. “We are proud to have attracted in Elisabeth Lackner a highly experienced and well-respected leader wit

Novartis today announced new data from the ALITHIOS open-label extension study. Data show first-line Kesimpta® (ofatumumab) treatment for up to six years led to less disability and disease progression in recently diagnosed (≤3 years) and treatment-naïve (RDTN) people with relapsing multiple sclerosis (RMS), compared to those who switched from teriflunomide1. A separate US-based single-arm OLIKOS Phase IIIb study showed that at 12 months, all clinically stable RMS patient

Takeda today committed JPY4.6 billion to five new Global Corporate Social Responsibility  partners as part of the company’s ongoing commitment to improving health systems resiliency in low and middle-income countries around the world. This commitment demonstrates Takeda’s focus on tackling systemic disparities and supporting local leadership in strengthening health infrastructure, empowering health workforce, and increasing local knowledge and capacity to improve equitable an

Brenus Pharma, a biotech company specializing in the development of cancer vaccines, announces the completion of a $25 million Series A financing round. The round is led by Angelor, an investment fund bringing together a cluster of investors from the Auvergne-Rhône-Alpes (AURA) region, including UI Investissement for the Fonds régional Avenir industrie Auvergne-Rhône-Alpes, Crédit Agricole Centre-France and Crédit Agricole Centre-Est, with 2 family o

Bavarian Nordic A/S and Gavi, the Vaccine Alliance today announced an advance purchase agreement (APA) to secure 500,000 doses of the MVA-BN® mpox vaccine (marketed as JYNNEOS® or IMVANEX®) to be supplied to countries in Africa impacted by the mpox outbreak. The doses will be for delivery in 2024. The vaccines will be funded by Gavi’s First Response Fund, a new financial mechanism created in June 2024 to make cash rapidly available to purchase vaccines in health em

with unresectable hepatocellular carcinoma (HCC) who had not received prior systemic therapy and were not eligible for localised treatment. These results from HIMALAYA will be presented today at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona, Spain (presentation 947MO). At five years of follow-up, this latest exploratory analysis showed that a single priming dose of Imjudo added to Imfinzi, called the STRIDE regimen (Single Tremelimumab Regular

Piramal Pharma Limited a leading global pharmaceuticals company, has embarked on its sustainability journey as the Science Based Targets initiative (SBTi) officially validated the company's near-term greenhouse gas (GHG) emission reduction targets. This validation aligns with Piramal Pharma's core purpose of 'Doing Well and Doing Good,' driving its business strategies and strengthening the company's commitment to making consistent, measurable progress toward a more su

GSK plc today announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China has granted Breakthrough Therapy Designation (BTD) for Blenrep (belantamab mafodotin) combined with bortezomib plus dexamethasone (BorDex) for the treatment of relapsed or refractory multiple myeloma. NMPA BTD is intended to expedite the development of therapies for serious and life-threatening diseases for which there are no existing treatments or where initial ev